Literature DB >> 16049570

Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition.

Mostafa El Mansari1, Pierre Blier.   

Abstract

BACKGROUND: The only antidepressant drugs that are effective in the treatment of obsessive-compulsive disorder (OCD) are those that effectively block the reuptake of serotonin (5-hydroxytryptamine; 5-HT). In humans, positron emission tomography studies have implicated the orbitofrontal cortex (OFC) in the mediation of OCD symptoms. In animals, administration of selective serotonin reuptake inhibitors (SSRIs) for 8 weeks (but not 3 weeks) led to increased release of 5-HT in the OFC, because of desensitization of the terminal 5-HT autoreceptors. However, the increase in synaptic levels of 5-HT in the OFC after long-term administration of SSRIs might be cancelled out by desensitization of postsynaptic 5-HT receptors. This study was undertaken to investigate if these OFC receptors adapt under such conditions.
METHODS: In vivo electrophysiologic techniques were used in this animal study. Male Sprague-Dawley rats received the SSRI paroxetine or vehicle control, delivered by implanted osmotic minipumps, for 3 or 8 weeks. With the rats under anesthesia, neuronal responsiveness to the microiontophoretic application of various drugs was assessed by determining the number of spikes suppressed per nanoampere of ejection current.
RESULTS: After administration of paroxetine for either 3 weeks or 8 weeks, there was no modification in the inhibitory effect of 5-HT, the preferential 5-HT(2A) receptor agonist (+)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride (DOI) or the preferential 5-HT(2C) receptor agonist 3-chlorophenyl piperazine dihydrochloride (mCPP). In contrast, the inhibitory effect of the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propilamino)-tetralin (8-OH-DPAT) was attenuated in the OFC after both 3 and 8 weeks of paroxetine administration.
CONCLUSION: These results indicate a desensitization of postsynaptic 5-HT(1A) receptors in the OFC but a lack of compensatory adaptation of the 5-HT receptor(s) mediating the main effect of 5-HT in this brain region. These observations imply that the activation of normosensitive postsynaptic 5-HT2-like receptors may mediate the effect of enhanced 5-HT release in the OFC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049570      PMCID: PMC1160562     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  40 in total

1.  Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist.

Authors:  Q Li; N A Muma; L D van de Kar
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

2.  Serotonin, psilocybin, and body dysmorphic disorder: a case report.

Authors:  K R Hanes
Journal:  J Clin Psychopharmacol       Date:  1996-04       Impact factor: 3.153

3.  Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Authors:  W K Goodman; L H Price; P L Delgado; J Palumbo; J H Krystal; L M Nagy; S A Rasmussen; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1990-06

4.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine.

Authors:  C Benkelfat; T E Nordahl; W E Semple; A C King; D L Murphy; R M Cohen
Journal:  Arch Gen Psychiatry       Date:  1990-09

5.  Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.

Authors:  K P Lesch; A Hoh; H M Schulte; M Osterheider; T Müller
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Current advances and trends in the treatment of depression.

Authors:  P Blier; C de Montigny
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

7.  Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene.

Authors:  P R Albert; Q Y Zhou; H H Van Tol; J R Bunzow; O Civelli
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

8.  Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Authors:  Stefano Erzegovesi; Emanuela Guglielmo; Francesca Siliprandi; Laura Bellodi
Journal:  Eur Neuropsychopharmacol       Date:  2005-01       Impact factor: 4.600

9.  Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.

Authors:  E Le Poul; N Laaris; E Doucet; A M Laporte; M Hamon; L Lanfumey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

10.  Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.

Authors:  M el Mansari; C Bouchard; P Blier
Journal:  Neuropsychopharmacology       Date:  1995-10       Impact factor: 7.853

View more
  11 in total

1.  Enduring Loss of Serotonergic Control of Orbitofrontal Cortex Function Following Contingent and Noncontingent Cocaine Exposure.

Authors:  Andrew M Wright; Agustin Zapata; Michael H Baumann; Joshua S Elmore; Alexander F Hoffman; Carl R Lupica
Journal:  Cereb Cortex       Date:  2017-12-01       Impact factor: 5.357

2.  Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.

Authors:  Jesse Wood; Yunbok Kim; Bita Moghaddam
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

Review 3.  5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Authors:  Alvaro L Garcia-Garcia; Adrian Newman-Tancredi; E David Leonardo
Journal:  Psychopharmacology (Berl)       Date:  2013-12-12       Impact factor: 4.530

4.  Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism.

Authors:  Jasmin M Dao; Susan C McQuown; Sandra E Loughlin; James D Belluzzi; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

5.  Norepinephrine-mediated regulation of 5HT1 receptor functioning in human platelets.

Authors:  M L Trincavelli; S Cuboni; M Montali; S Santaguida; A Lucacchini; C Martini
Journal:  Neurochem Res       Date:  2008-02-13       Impact factor: 3.996

6.  Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.

Authors:  Nancy S Woehrle; Stephanie J Klenotich; Naseem Jamnia; Emily V Ho; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2013-02-03       Impact factor: 4.530

Review 7.  Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD.

Authors:  Benjamin D Greenberg; Scott L Rauch; Suzanne N Haber
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 8.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

9.  Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.

Authors:  Pia Baldinger; Anna S Höflich; Markus Mitterhauser; Andreas Hahn; Christina Rami-Mark; Marie Spies; Wolfgang Wadsak; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Neurochemical modulation of response inhibition and probabilistic learning in humans.

Authors:  Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Luke Clark; Trevor W Robbins; Barbara J Sahakian
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.